₹537.6
▲ +2.94 +0.55%
17 Jul 2026
NSE Listed · Pharmaceuticals
Amrutajan Health Ltd. (AMRUTANJAN)
Volume: 102Avg Vol 1W: 11,956Avg Vol 1M: 60,73752W Range:₹486₹790.95
Key Ratios
Checked 4h agoMarket Cap₹1,536 Cr
Current Price₹537.6
Previous Close₹534.66
High / Low (52w)₹790.95 / ₹486
Volume102
Avg Vol (1W)11,956
Avg Vol (1M)60,737
Stock P/E23.82
Book Value₹128.06
Dividend Yield92%
ROE17.42%
ROA11.38%
Revenue (TTM)—
Revenue Growth12.11%
Profit Margin11.52%
Total Debt₹0 Cr
Shares Outstanding3 Cr
Face Value₹1
EPS (TTM)₹22.31
P/B4.15
Debt / Equity0.02
50 DMA₹541.46
200 DMA₹550.8
Day change+0.55%
Price Chart
₹537.6▼ 21.24% · 1Y
2025-11-252026-07-17
20-day avg volume: 57K shares
Pros
- Healthy return on equity of 17.4%.
- Pays a dividend yield of 92.0%.
- Company is almost debt-free.
- Revenue grew 12% YoY.
- Net profit is growing year over year.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹84 Cr | ₹110 Cr | ₹123 Cr | ₹135 Cr | ₹94 Cr | ₹118 Cr | ₹141 Cr | ₹150 Cr |
| EBITDA | ₹6 Cr | ₹16 Cr | ₹26 Cr | ₹21 Cr | ₹11 Cr | ₹19 Cr | ₹28 Cr | ₹29 Cr |
| Net Profit | ₹5 Cr | ₹12 Cr | ₹19 Cr | ₹15 Cr | ₹8 Cr | ₹14 Cr | ₹19 Cr | ₹16 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|
| Revenue | ₹110 Cr | ₹148 Cr | ₹142 Cr | ₹145 Cr | ₹171 Cr | ₹192 Cr |
| EBITDA | ₹16 Cr | ₹19 Cr | ₹18 Cr | ₹21 Cr | ₹25 Cr | ₹33 Cr |
| Net Profit | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹12 Cr | ₹15 Cr | ₹21 Cr |
| EPS | 33.7 | 32.47 | 6.92 | 8.51 | 10.31 | 14.08 |
Balance Sheet
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|
| Total Assets | ₹157 Cr | ₹124 Cr | ₹124 Cr | ₹120 Cr | ₹124 Cr | ₹140 Cr |
| Total Liabilities | ₹55 Cr | ₹47 Cr | ₹42 Cr | ₹31 Cr | ₹29 Cr | ₹32 Cr |
| Equity | ₹101 Cr | ₹77 Cr | ₹82 Cr | ₹89 Cr | ₹95 Cr | ₹109 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|
| Operating | ₹10 Cr | ₹9 Cr | ₹14 Cr | ₹25 Cr | ₹28 Cr | ₹32 Cr |
| Investing | ₹-29 Cr | ₹14 Cr | ₹8 Cr | ₹16 Cr | ₹-5 Cr | ₹4 Cr |
| Financing | ₹20 Cr | ₹-27 Cr | ₹-14 Cr | ₹-14 Cr | ₹-12 Cr | ₹-13 Cr |
| Free Cash Flow | ₹10 Cr | ₹9 Cr | ₹14 Cr | ₹25 Cr | ₹28 Cr | ₹32 Cr |
Shareholding
Promoter 46.52% Institutions 14.72% Public 38.76%
Efficiency & Working Capital
ROCE21.9%
Interest Coverage75.3
Dividend Payout—
Debtor Days51 d
Inventory Days17 d
Payable Days17 d
Cash Conversion Cycle51 d
Working Capital Days68 d
Shareholding Details
As of 2026-06-30
Promoter46.5%
FII2.4%
DII12.3%
Institutions14.7%
Public38.8%
Promoter Pledge0%
No. of Shareholders45,135
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.6% | 50.6% | 50.6% | 50.6% | 46.5% | 46.5% | 46.5% | 46.5% | 46.5% | 46.5% | 46.5% | 46.5% |
| FIIs | 0.7% | 0.8% | 1.4% | 1.5% | 2.3% | 2.3% | 2.3% | 2.4% | 2.4% | 2.3% | 2.2% | 2.4% |
| DIIs | 7.1% | 6.9% | 7.3% | 7.3% | 10.6% | 11.1% | 11.4% | 12.7% | 12.9% | 13% | 12.7% | 12.3% |
| Public | 41.6% | 41.7% | 40.7% | 40.5% | 40.5% | 40.1% | 39.8% | 38.4% | 38.2% | 38.2% | 38.6% | 38.8% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 72,002 | 68,404 | 62,664 | 57,169 | 54,536 | 53,856 | 51,674 | 49,431 | 47,954 | 46,675 | 45,805 | 45,135 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Goodhealth Holdings Private Limited | Shareholding of Promoter and Promoter Group | 20.2% | 58,25,803 |
| Sambhuprasad Sivalenka | Shareholding of Promoter and Promoter Group | 10.3% | 29,90,730 |
| Ramaa Prabhakar Arikirevula | Shareholding of Promoter and Promoter Group | 4.7% | 13,71,530 |
| Dsp Small Cap Fund | Public Shareholding | 3.8% | 10,98,167 |
| Sambhu Prasad Sivalenka | Shareholding of Promoter and Promoter Group | 3.6% | 10,40,171 |
| Ramaa Prabhakar Arikirevula | Shareholding of Promoter and Promoter Group | 3% | 8,72,535 |
| Carnelian Bharat Amritkaal Fund . | Public Shareholding | 3% | 8,60,403 |
| Ramalingam Ganti | Shareholding of Promoter and Promoter Group | 2.5% | 7,30,640 |
| Amulya Kamakshi Priya Arikirevula | Shareholding of Promoter and Promoter Group | 2.1% | 6,16,781 |
| Icici Prudential Fmcg Fund | Public Shareholding | 2% | 5,80,411 |
| Dipak Kanayalal Shah | Public Shareholding | 1.1% | 3,25,000 |
| Carnelian Structural Shift Fund | Public Shareholding | 1.1% | 3,15,000 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Sambhu Prasad Sivalenka | 0 | 0% | 2026-06-30 |
| Ramaa Prabhakar Arikirevula | 0 | 0% | 2026-06-30 |
| Amulya Kamakshi Priya Arikirevula | 0 | 0% | 2026-06-30 |
| Goodhealth Holdings Private Limited | 0 | 0% | 2026-06-30 |
| Sambhuprasad Sivalenka | 0 | 0% | 2026-06-30 |
| Ramaa Prabhakar Arikirevula | 0 | 0% | 2026-06-30 |
| Ramalingam Ganti | 0 | 0% | 2026-06-30 |
| Dsp Small Cap Fund | 0 | 0% | 2026-06-30 |
| Icici Prudential Fmcg Fund | 0 | 0% | 2026-06-30 |
| Carnelian Bharat Amritkaal Fund . | 0 | 0% | 2026-06-30 |
| Carnelian Structural Shift Fund | 0 | 0% | 2026-06-30 |
| Dipak Kanayalal Shah | 0 | 0% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| S Sambhuprasad | Chairman / Executive Director / M D / Promoter | 2025 |
| Ramaa Prabhakar Arikirevula | Non-Exec & Non-Independent Dir | 2025 |
| G Raghavan | Non-Exec & Non-Independent Dir | 2025 |
| V Raja | Independent Non Exe. Director | 2025 |
| Muralidharan Swayambunathan | Independent Non Exe. Director | 2025 |
| Meena Lochani Raghunathan | Independent Non Exe. Director | 2025 |
| V Nagaraj | Independent Non Exe. Director | 2025 |
| GAGAN PREET SINGH | CS / Compliance Officer / General Manager - Legal | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| OTC Products | ₹290 Cr | 64.2% |
| Women's Hygiene | ₹124 Cr | 27.4% |
| Beverages | ₹36 Cr | 8.1% |
| Others | ₹1 Cr | 0.3% |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹442 Cr | 98.2% |
| Rest of the world | ₹8 Cr | 1.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 5 | 3 | 3 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2026-02-06 | ₹1 (100%) | Interim 2 |
| dividend | 2025-11-18 | ₹1 (100%) | Interim 1 |
| dividend | 2025-09-16 | ₹2.6 (260%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 4 | 3 | 7 |
| 2025 | 0 | 0 | 0 | 4 | 3 | 7 |
| 2025 | 0 | 0 | 0 | 4 | 3 | 7 |
Insider / Designated-Person Trades
30 recent disclosure(s)
S JeyakanthDisposal · 1,400
Nageswaramma Private TrustDisposal · 3,40,275
Nageswaramma Private TrustDisposal · 8,32,725
Amulya Kamakshi Priya ArikirevulaAcquisition · 6,16,781
RAMAA P ARIKIREVULAAcquisition · 2,64,335
S SAMBHU PRASAD EXECUTOR TO THE ESTATE OF S RAMAYAMMADisposal · 22,54,790
Substantial Acquisitions (SAST)
12 disclosure(s)
Market27/09/2024 · 3,40,275
Market26/09/2024 · 8,32,725
Transmission12/06/2024 · 36,530
Transmission28/05/2024 · —
Transmission02/05/2024 · 4,420
Transmission02/05/2024 · 4,420
Company Information
Incorporated1936
ChairmanS Sambhuprasad
AuditorB S R & Co LLP
Investor Email[email protected]; customercare@amrutanjan.
📍 New 103 Old 42-45 LuzChurch Rd, Mylapore, Chennai, Tamil Nadu, 600004
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search